Why the study?
Surgeons must manage patients requiring emergency surgery while receiving DOACs such as dabigatran, which can be reversed with idarucizumab.
Does idarucizumab prevent excessive bleeding in a patient on dabigatran requiring emergency surgery?
Does idarucizumab prevent excessive bleeding in a patient on dabigatran requiring emergency surgery?
Idarucizumab successfully and rapidly reversed the anticoagulant effect of dabigatran, allowing for safe emergency surgery without excessive bleeding.
Dabigatran may complicate emergency abdominal surgery; leaves open optimal reversal strategies in NOAC patients.
Surgeons are required to keep themselves updated on ever-increasing list of drugs that may influence the outcomes of surgeries, especially in an emergency scenario. Here, we report a case of acute abdomen, wherein the patient was on dabigatran, a ‘Non-vit. K/Direct Oral Anti-Coagulant’ (NOAC/DOAC). NOACs are relatively recent additions to anticoagulation care. In our patient, dabigatran was prescribed by a cardiologist to prevent the occurrence of stroke in the patient who was suffering from atrial fibrillation. In case of uncontrolled bleeding, or when an emergency surgery is needed, the effect of dabigatran can be reversed with the use of a specific monoclonal antibody – idarucizumab. Knowledge about the drug & its reversal agent, and a multi-disciplinary approach, could make it possible for us to operate on the patient, and avoid excessive bleeding during the surgery.
No takes yet. Share an insight, caveat, or question.
Dahiya et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: